
Sign up to save your podcasts
Or


In our second episode of the “Immuno Oncology Talks”, Associate Professor Evren Alici, from the Karolinska Institutet in Sweden, was invited to discuss NK cell-based cancer immunotherapies, accompanied by his colleague Professor Hans-Gustaf Ljunggren. The primary focus of Professor Alici´s research is on novel NK cell-based therapies, and includes generation and testing of genetically engineered NK cells, like chimeric receptor and CAR-NK cells. Associate Professor Alici is also co-director of the NextGenNK Competence Center (https://ki.se/en/research/nextgennk).
MAT-BE-2200747 (ver 1.0) 09 2022
By SanofiIn our second episode of the “Immuno Oncology Talks”, Associate Professor Evren Alici, from the Karolinska Institutet in Sweden, was invited to discuss NK cell-based cancer immunotherapies, accompanied by his colleague Professor Hans-Gustaf Ljunggren. The primary focus of Professor Alici´s research is on novel NK cell-based therapies, and includes generation and testing of genetically engineered NK cells, like chimeric receptor and CAR-NK cells. Associate Professor Alici is also co-director of the NextGenNK Competence Center (https://ki.se/en/research/nextgennk).
MAT-BE-2200747 (ver 1.0) 09 2022